Biogen Pharmachem Industries (531752) Q4 15/16 earnings summary

Executive summary

• Operations were inactive in FY15/16 amid financial crisis and working-capital scarcity; revenue was nil and net loss was ₹281,764, versus ₹1,327,795 in FY14/15.

• Management said it was pursuing cost reductions and seeking an opportunity to restart operations.

Financial highlights

• Revenue from operations and total revenue were nil in FY15/16; total expenses were ₹281,764, down from ₹1,362,885 in FY14/15.

• Net loss was ₹281,764, compared with ₹1,327,795 in FY14/15; basic and diluted EPS were reported as ₹0.00.

• Total assets were ₹688.09m at 31 Mar 2016, versus ₹734.86m a year earlier; cash and cash equivalents were ₹1.28m.

• Operating cash flow was ₹4.68m and net cash increased ₹0.25m; cash at year-end was ₹1.28m.

Outlook and guidance

• Future development depends on resuming operations; working-capital scarcity remained a constraint, while cost-cutting measures were underway.

• The board was seeking an opportunity to make operations active again; no quantified financial guidance was stated.